JP2007513095A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007513095A5 JP2007513095A5 JP2006541759A JP2006541759A JP2007513095A5 JP 2007513095 A5 JP2007513095 A5 JP 2007513095A5 JP 2006541759 A JP2006541759 A JP 2006541759A JP 2006541759 A JP2006541759 A JP 2006541759A JP 2007513095 A5 JP2007513095 A5 JP 2007513095A5
- Authority
- JP
- Japan
- Prior art keywords
- pipamperon
- compound
- selective serotonin
- reuptake inhibitor
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 9
- 239000004480 active ingredient Substances 0.000 claims 8
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 claims 6
- 229960001653 citalopram Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 3
- ZEUITGRIYCTCEM-KRWDZBQOSA-N Duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 3
- 206010014551 Emotional disease Diseases 0.000 claims 3
- 229960002464 Fluoxetine Drugs 0.000 claims 3
- 229960004038 Fluvoxamine Drugs 0.000 claims 3
- GJJFMKBJSRMPLA-HIFRSBDPSA-N Milnacipran Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims 3
- 229960000600 Milnacipran Drugs 0.000 claims 3
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 claims 3
- VGKDLMBJGBXTGI-SJCJKPOMSA-N Sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 3
- 229960002073 Sertraline Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229960002866 duloxetine Drugs 0.000 claims 3
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 3
- 229960002296 paroxetine Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrugs Drugs 0.000 claims 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 3
- 229960004688 venlafaxine Drugs 0.000 claims 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229940076279 Serotonin Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/725,965 US7884096B2 (en) | 2003-12-02 | 2003-12-02 | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CA2451798A CA2451798C (en) | 2003-12-02 | 2003-12-02 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| EP03447279A EP1547650A1 (en) | 2003-12-02 | 2003-12-02 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP04447001 | 2004-01-05 | ||
| US10/752,423 US7855195B2 (en) | 2003-12-02 | 2004-01-06 | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP04447066A EP1576985A1 (en) | 2004-03-18 | 2004-03-18 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US10/803,793 US20050119249A1 (en) | 2003-12-02 | 2004-03-18 | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CA 2461248 CA2461248C (en) | 2003-12-02 | 2004-03-18 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| EP04025035A EP1541197B8 (en) | 2003-12-02 | 2004-10-21 | Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders |
| US10/984,683 US20050203130A1 (en) | 2003-12-02 | 2004-11-09 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| PCT/BE2004/000172 WO2005053796A1 (en) | 2003-12-02 | 2004-12-02 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007513095A JP2007513095A (ja) | 2007-05-24 |
| JP2007513095A5 true JP2007513095A5 (zh) | 2007-12-27 |
| JP4571645B2 JP4571645B2 (ja) | 2010-10-27 |
Family
ID=38156741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541759A Expired - Fee Related JP4571645B2 (ja) | 2003-12-02 | 2004-12-02 | Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4571645B2 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1541197T3 (da) * | 2003-12-02 | 2009-06-15 | Pharmaneuroboost N V | Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser |
| CN101983193B (zh) * | 2008-01-31 | 2014-03-12 | 武田药品工业株式会社 | 注意缺陷/多动障碍的预防或治疗剂 |
| US8895609B2 (en) | 2009-11-06 | 2014-11-25 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| JP6466792B2 (ja) * | 2015-07-03 | 2019-02-06 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 注意欠陥／多動性障害（ａｄｈｄ）の治療方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1541197T3 (da) * | 2003-12-02 | 2009-06-15 | Pharmaneuroboost N V | Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser |
-
2004
- 2004-12-02 JP JP2006541759A patent/JP4571645B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022180461A5 (zh) | ||
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| JP2005512995A5 (zh) | ||
| JP2013544850A5 (zh) | ||
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| SK14612003A3 (sk) | Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu | |
| JP2006504795A5 (zh) | ||
| JP2010530422A (ja) | うつ病のための組合せ治療 | |
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| JP2007510736A5 (zh) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2013536837A5 (zh) | ||
| JP2008503445A5 (zh) | ||
| RU2008110933A (ru) | Применение амброксола для лечения риновирусных инфекций | |
| AR073435A1 (es) | Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| JP2016505050A5 (zh) | ||
| JP2011500589A5 (zh) | ||
| JP2005519936A5 (zh) | ||
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний |